ArticleMethodsX2020
Titration methods for rVSV-based vaccine manufacturing.
Article in MethodsX, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Production of the Bakırköy strain of sheeppox vaccine virus in spinner flasks using an alternative method with Cytodex 1 microcarriers on Vero cells.BMC biotechnology · 2025Article
- An HPLC-SEC-based rapid quantification method for vesicular stomatitis virus particles to facilitate process development.Molecular therapy. Methods & clinical development · 2024Article
- Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine.Vaccines · 2023Article
- Optimization of VSV-ΔG-spike production process with the Ambr15 system for a SARS-COV-2 vaccine.Biotechnology and bioengineering · 2022Article
- Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies.NPJ vaccines · 2022Review
- Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures.Vaccines · 2021Article
- Review
- Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.Biotechnology and bioengineering · 2021Article
- Considerations for bioanalytical characterization and batch release of COVID-19 vaccines.NPJ vaccines · 2021Review
- The Propagation, Quantification, and Storage of Vesicular Stomatitis Virus.Current protocols in microbiology · 2020Article
- Rhabdovirus Infection Is Dependent on Serine/Threonine Kinase AP2-Associated Kinase 1.Life (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recombinant Vesicular Stomatitis Virus (rVSV) is an emerging platform for viral vector-based vaccines. Promising results have been reported in clinical trials for the rVSV-ZEBOV vaccine for Ebola virus disease prevention. In this study, we describe the titration tools elaborated to assess the titre of rVSV-ZEBOV productions. • A streamlined Median Tissue Culture Infectious Dose (TCID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.